Terms of Use

Ligand Pharmaceuticals, Inc. Legal Policy

Caution Regarding Forward-Looking Statements

This website may contain forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of the latest press release. These statements include those related to translating value building shareholder value, potential blockbuster compounds and the "new" Ligand. Actual events or results may differ from Ligand's expectations. Forward-looking statements are only predictions and are subject to a number of risks and uncertainties. Actual events and results may differ significantly from those discussed at this site, due to factors including research, development, commercial and market risks.

While forward-looking statements reflect our good faith beliefs (or those of the indicated third parties), they are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Additional risks and uncertainties are described in the Company's disclosure documents filed with the Securities and Exchange Commission, such as it’s most current Forms 10-K and 10-Q, copies of which are available online or from the Company upon request. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Trademarks and Copyrights

"Ligand" and the Ligand logo are trademarks of Ligand Pharmaceuticals, Inc.

This site is copyrighted, Ligand Pharmaceuticals, Inc. All rights reserved.

Ligand Pharmaceuticals, Inc. Privacy Policy

Internet Privacy Policy

Welcome to Ligand Pharmaceuticals' Web site. This Web site is owned by Ligand Pharmaceuticals. The purpose of this Privacy Policy is to inform you about our practices regarding collection, use, and disclosure of information published on this Web site.

Your Consent

By using this Web site, you agree to the terms of this Privacy Policy.

Whenever you submit information through the Web site, you consent to the collection and use of that information in accordance with this Privacy Policy.

Privacy Policy

Ligand Pharmaceuticals is committed to protecting your right to privacy.

The personal information submitted through our Investor Relations E-mail Alerts is not disclosed, made available, or otherwise used for purposes other than those specified at the time of collection, except with your consent or as authorized by law or regulation.

Privacy concerns specific to Ligand Pharmaceuticals are as follows:

While on the E-mail Alerts section on the Ligand Pharmaceuticals Web site, you may be asked to provide identifiable information, such as name, mailing address, telephone number and e-mail address.

Ligand Pharmaceuticals will only gather information through lawful means.

When you view information on the Ligand Pharmaceuticals Web site, some non-confidential data may be collected, such as your access time and date and the Web sections you visited. The Ligand Pharmaceuticals Web site may also subsequently retrieve simple text files known as "cookies" that may identify you and your computer to our Internet site. Cookies do not contain personal or confidential information and will only be used to monitor activity on this Web site.

Ligand Pharmaceuticals will not distribute or sell your information.

Ligand Pharmaceuticals will only use personal information submitted by you in order to provide publicly disclosed information.

While we make reasonable efforts to include accurate and up-to-date information on the Ligand Pharmaceuticals Web site, content is provided by a variety of sources and may frequently change; therefore, Ligand Pharmaceuticals cannot make any representations or warranties as to the accuracy of information. Ligand Pharmaceuticals assumes no liability or responsibility for any errors or omissions in the content of the Web site.

If you have any questions or concerns regarding Ligand Pharmaceuticals' Web site and or this privacy policy please contact Erika Luib in Investor Relations at 858-550-7896, eluib@ligand.com.